TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3
B: Arm Label: Reference Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Tested Drug; Type: EXPERIMENTAL; Interventions: Drug: Triamcinolone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Reference Drug | Intervention Type: DRUG; Name: Triamcinolone; Assigned to Arm(s): Tested Drug
C: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
D: Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline Associated With Intensive Counselling Versus Placebo of Varenicline Associated With Intensive Counselling on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). A Multicenter Randomized Double-blind Trial
Brief Summary: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the bronchi with an increasing prevalence. By 2020, the mortality related to COPD is expected to become the 3rd leading death worldwide. COPD is caused by smoking in approximately 90 % of the cases. Nevertheless, COPD remains under-diagnosed and more than half of patients remain active smokers. Brittany is the second region of France facing an abnormal high death rate related to COPD. Smoking cessation is the most effective therapeutic approach to reduce the evolution of the disease, the frequency of the exacerbations and the the mortality. Besides, smoking cessation is associated with a reduced risk of cardiovascular events and cancer. Given the COPD patients' strong addiction, smoking cessation is not easily obtained in such population. Furthermore, smoking cessation has been underestimated in several studies. Most of these studies evaluated various methods of smoking cessation in COPD patients performed after an exacerbation, which has a hospitalization related mortality of approximately 10%. Thus, there is an urgent need to find effective pharmacotherapies to help COPD patients to cease smoking. Varenicline, a partial agonist at a4ß2 nicotinic acetylcholine receptors is reported to be one of the most effective pharmacotherapies for smoking cessation. However, it has never been evaluated at the acute phase of an exacerbation of COPD requiring hospitalization.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline with counselling; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo with counselling; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline with counselling | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo with counselling
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Very Early Rehabilitation Compared With Conventional Rehabilitation in Acute Ischemic Stroke in the Vascular Unit of the Hospital de Clínicas de Porto Alegre - HCPA
Brief Summary: The purpose of this study is to evaluate the effectiveness of a rehabilitation (physiotherapy) program in patients with acute ischemic stroke in Acute Vascular Unit and in general ward of Hospital de Clínicas de Porto Alegre, and to verify the degree of disability at fourteenth and third month, functional improvement at third month, the frequency of deaths and incidence of complications due to immobility and quantify the time spent in hospital.


Options:
A: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC
B: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization
C: Arm Label: enhanced upper-extremity program, EUEP; Type: EXPERIMENTAL; Interventions: Other: UFT | Arm Label: enhanced lower-extremity program,ELLP); Type: EXPERIMENTAL; Interventions: Other: LFT | Intervention Type: OTHER; Name: UFT; Assigned to Arm(s): enhanced upper-extremity program, EUEP | Intervention Type: OTHER; Name: LFT; Assigned to Arm(s): enhanced lower-extremity program,ELLP)
D: Arm Label: usual management; Type: OTHER; Interventions: Other: no physical activity | Arm Label: physical training; Type: EXPERIMENTAL; Interventions: Other: physical activity | Intervention Type: OTHER; Name: no physical activity; Assigned to Arm(s): usual management | Intervention Type: OTHER; Name: physical activity; Assigned to Arm(s): physical training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Very Early Rehabilitation Compared With Conventional Rehabilitation in Acute Ischemic Stroke in the Vascular Unit of the Hospital de Clínicas de Porto Alegre - HCPA
Brief Summary: The purpose of this study is to evaluate the effectiveness of a rehabilitation (physiotherapy) program in patients with acute ischemic stroke in Acute Vascular Unit and in general ward of Hospital de Clínicas de Porto Alegre, and to verify the degree of disability at fourteenth and third month, functional improvement at third month, the frequency of deaths and incidence of complications due to immobility and quantify the time spent in hospital.


Options:
A: Intervention Type: OTHER; Name: Visumotor Upper Extremity Training; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Anodal/Sham tDCS; Assigned to Arm(s): N/A
B: Arm Label: CIMT + active anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: active anodal transcranial Direct Current Stimulation (tDCS), Behavioral: Constraint Induced Movement Therapy (CIMT) | Arm Label: CIMT + sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: sham transcranial Direct Current Stimulation, Behavioral: Constraint Induced Movement Therapy (CIMT) | Arm Label: Healthy control subjects; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: active anodal transcranial Direct Current Stimulation (tDCS); Assigned to Arm(s): CIMT + active anodal tDCS | Intervention Type: DEVICE; Name: sham transcranial Direct Current Stimulation; Assigned to Arm(s): CIMT + sham tDCS | Intervention Type: BEHAVIORAL; Name: Constraint Induced Movement Therapy (CIMT); Assigned to Arm(s): CIMT + active anodal tDCS, CIMT + sham tDCS
C: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization
D: Arm Label: Variable high-intensity Training; Type: EXPERIMENTAL; Interventions: Behavioral: exercise | Arm Label: Variable low-intensity training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Arm Label: Constant High Intensity Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): Constant High Intensity Training, Variable high-intensity Training, Variable low-intensity training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of an ED-initiated Online Asthma Management Program for Urban Teens (Puff City-ED)
Brief Summary: The objective of this study is to determine the feasibility of conducting a randomized controlled trial to evaluate the effectiveness of an online, Emergency Department-initiated asthma management intervention designed to reduce asthma-related morbidity among urban teenagers aged 13-19 years with uncontrolled asthma. The study will examine issues around recruitment, participant compliance with the study protocol, Internet access, and attrition. Investigators will first develop a protocol for recruiting 13-19 year old patients with acute asthma into an ED-initiated pilot trial of an online asthma management program, describing recruitment and refusal rates. Investigators will measure participant compliance with the pilot study protocol including 4 online sessions and a 6 month survey. Investigators will also measure compliance of the participants parents at baseline and a six month follow up. Investigators will then use pilot study results to describe the intervention effect on selected outcomes including ED visits, asthma control as measured by Asthma Control Questionnaire, functional limitations, quality of life, and behavior change.


Options:
A: Arm Label: Active Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Feedback | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Active Feedback | Intervention Type: BEHAVIORAL; Name: Active Feedback; Assigned to Arm(s): Active Feedback, Control
B: Arm Label: CampAir Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CampAir | Arm Label: Information and Referral Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information and Referral | Intervention Type: BEHAVIORAL; Name: CampAir; Assigned to Arm(s): CampAir Intervention | Intervention Type: BEHAVIORAL; Name: Information and Referral; Assigned to Arm(s): Information and Referral Control
C: Arm Label: Tailored asthma management program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored asthma management program | Arm Label: Generic web-based education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based education | Intervention Type: BEHAVIORAL; Name: Tailored asthma management program; Assigned to Arm(s): Tailored asthma management program | Intervention Type: BEHAVIORAL; Name: Generic web-based education; Assigned to Arm(s): Generic web-based education
D: Arm Label: CHESS + Case Mgt; Type: EXPERIMENTAL; Interventions: Behavioral: CHESS Internet telehealth | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHESS Internet telehealth; Assigned to Arm(s): CHESS + Case Mgt

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of β-carotene Biofortified Maize in Improving Vitamin A Status and Reducing the Prevalence of Vitamin A Deficiency Among Children in Rural Zambia
Brief Summary: The purpose of this cluster-randomized trial is to examine whether daily consumption of β-carotene biofortified maize flour can reduce the prevalence of vitamin A deficiency and improve the vitamin A status and among 4-8 year old children in rural Zambia.


Options:
A: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White
B: Arm Label: White Maize Flour; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: White Maize Flour | Arm Label: β-Carotene Biofortified Maize; Type: EXPERIMENTAL; Interventions: Dietary Supplement: β-Carotene Biofortified Maize Flour | Arm Label: Non-Intervened; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: β-Carotene Biofortified Maize Flour; Assigned to Arm(s): β-Carotene Biofortified Maize | Intervention Type: DIETARY_SUPPLEMENT; Name: White Maize Flour; Assigned to Arm(s): White Maize Flour
C: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
D: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Brief Summary: This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
B: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe
D: Arm Label: Ixekizumab Q2W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Ixekizumab Q4W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adalimumab Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab Q2W, Ixekizumab Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Q2W

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Brief Summary: This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.


Options:
A: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ixekizumab Q2W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Ixekizumab Q4W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adalimumab Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab Q2W, Ixekizumab Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Q2W
C: Arm Label: 10 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 25 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 75 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 150 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Ixekizumab, Drug: Placebo | Arm Label: 120 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 80 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Intervention Type: BIOLOGICAL; Name: Ixekizumab; Assigned to Arm(s): 10 mg Ixekizumab, 120 mg Ixekizumab, 150 mg Ixekizumab, 25 mg Ixekizumab, 75 mg Ixekizumab, 80 mg Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Brief Summary: This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.


Options:
A: Arm Label: Ixekizumab Q2W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Ixekizumab Q4W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adalimumab Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab Q2W, Ixekizumab Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Q2W
B: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
C: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
D: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg

Answer: A